← Back to Search

Thrombectomy System

CAPERE Thrombectomy System for Arteriovenous Graft Thrombosis (AVATR Trial)

N/A
Waitlist Available
Led By Sebastian Mafeld, MD
Research Sponsored by Vascular Medcure, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Dialysis patients with clinical signs, symptoms and presentation consistent with acute thrombosis; onset of symptoms ≤ 14 days
Dialysis patients who are ≥ 18 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up open
Awards & highlights

AVATR Trial Summary

This study is evaluating whether a new device can remove blood clots from a patient's blood vessels.

Eligible Conditions
  • Arteriovenous Graft Thrombosis

AVATR Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

AVATR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~intraoperative
This trial's timeline: 3 weeks for screening, Varies for treatment, and intraoperative for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Endpoint (Effectiveness)
Safety Evaluation
Secondary outcome measures
30-Day Patency Rate
Clinical Success
Device Safety
+2 more

AVATR Trial Design

1Treatment groups
Experimental Treatment
Group I: AVATR-TorontoExperimental Treatment1 Intervention
Thrombectomy of arteriovenous graft using CAPERE Thrombectomy System

Find a Location

Who is running the clinical trial?

Vascular Medcure, Inc.Lead Sponsor
1 Previous Clinical Trials
18 Total Patients Enrolled
Medtronic EndovascularLead Sponsor
68 Previous Clinical Trials
14,946 Total Patients Enrolled
Sebastian Mafeld, MDPrincipal InvestigatorUniversity Health Network Toronto General

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Mar 2025